Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer 
    		2015 ASCO Annual Meeting
    	
    	
    	
    
        Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).
    
    
    
    
       
       
    		Carolyn Jean Presley, MD, and James L. Mulshine, MD
		
		
        
		
		
		
		James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).
			
			
     	
    
       
       
    		Jame Abraham, MD
		
		
        
		
		
		
		Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).
			
			
     	
    
       
       
    		John L. Marshall, MD
		
		
        
		
		
		
		John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
			
			
     	
    
       
       
    		John Smyth, MD
		
		
        
		
		
		
		John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
			
			
     	
    
       
       
    		James H. Doroshow, MD
		
		
        
		
		
		
		James H. Doroshow, MD, of the National Cancer Institute, describes a new precision medicine initiative called the MATCH trial: Molecular Analysis for Therapy Choice. In 2,400 NCI clinical trial sites, 3,000 patients will be screened and their tumors analyzed to determine whether they contain genetic abnormalities for which a targeted drug exists.